Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00568308




Registration number
NCT00568308
Ethics application status
Date submitted
4/12/2007
Date registered
6/12/2007
Date last updated
15/06/2011

Titles & IDs
Public title
Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma
Scientific title
A Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, International, Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma
Secondary ID [1] 0 0
PR88302
Universal Trial Number (UTN)
Trial acronym
PATHWAY
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cancer 0 0
Liver Cancer 0 0
Primary Liver Cancer 0 0
Hepatocellular Carcinoma 0 0
Hepatoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Liver
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PI-88
Treatment: Drugs - placebo

Placebo comparator: 1 -

Experimental: 2 -


Treatment: Drugs: PI-88
160mg subcutaneous injection

Treatment: Drugs: placebo
matched placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Disease-free Survival
Timepoint [1] 0 0
End of Study
Secondary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
End of study
Secondary outcome [2] 0 0
Time to Recurrence
Timepoint [2] 0 0
End of Study
Secondary outcome [3] 0 0
Quality of Life
Timepoint [3] 0 0
End of Study
Secondary outcome [4] 0 0
Safety and Tolerability
Timepoint [4] 0 0
End of Study
Secondary outcome [5] 0 0
Compliance
Timepoint [5] 0 0
End of Study

Eligibility
Key inclusion criteria
Key

* Histologically-proven primary hepatocellular carcinoma with curative resection performed in the 4 - 6 weeks prior to randomisation.
* ECOG performance status 0 to 2
* Child Pugh classification A or B

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any evidence of tumour metastasis or co-existing malignant disease
* Any prior recurrence of HCC or any liver resection prior to the most recent procedure
* History of prior HCC therapy

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/07/2008
Sample size
Target
600
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Australia
Recruitment postcode(s) [1] 0 0
- Australia
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
New York
Country [2] 0 0
Canada
State/province [2] 0 0
Canada
Country [3] 0 0
Hong Kong
State/province [3] 0 0
Hong Kong
Country [4] 0 0
Italy
State/province [4] 0 0
Italy
Country [5] 0 0
Malaysia
State/province [5] 0 0
Malaysia
Country [6] 0 0
Singapore
State/province [6] 0 0
Singapore
Country [7] 0 0
Spain
State/province [7] 0 0
Spain
Country [8] 0 0
Taiwan
State/province [8] 0 0
Taiwan
Country [9] 0 0
Thailand
State/province [9] 0 0
Thailand

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Progen Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.
Trial website
https://clinicaltrials.gov/study/NCT00568308
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Ronnie TP Poon, MD
Address 0 0
University of Hong Kong, Queen Mary Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00568308